Literature DB >> 14756243

Cathepsins in the osteoclast.

Tetsuya Goto1, Takayoshi Yamaza, Teruo Tanaka.   

Abstract

The mechanism by which bone collagen and other organic components are degraded by the osteoclast during osteoclastic bone resorption was unclear until the 1980s. Studies conducted since the early 1990s have identified lysosomal proteases, mainly cathepsins that are active at low pH, involved in osteoclastic bone resorption. Several cathepsins, such as cathepsins C, D, B, E, G and L, were initially demonstrated to take part in the degradation of organic bone matrix in osteoclasts. Cathepsin K, which has high proteolytic activity and localizes primarily in osteoclasts, was discovered in 1995. This first tissue-specific cathepsin was associated with pycnodysostosis, a genetic disorder observable as an osteopetrotic phenotype in cathepsin K-deficient mice. Cystatin C, an endogenous inhibitor of cysteine proteases, regulates the activity of cathepsin K. However, detailed morphological observations suggest that the organic bone matrix is degraded by not only cathepsin K, but also by matrix metalloproteinases or other cathepsins. The osteoclast possesses a unique endocytotic/exocytotic structure and each cathepsin is specifically localized in the osteoclast, which implies that each cathepsin contributes cooperatively to the process of osteoclastic bone resorption. Further studies may clarify the regulation of cathepsin activities and the roles of cathepsins during bone remodelling.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14756243     DOI: 10.1093/jmicro/52.6.551

Source DB:  PubMed          Journal:  J Electron Microsc (Tokyo)        ISSN: 0022-0744


  23 in total

1.  SERPINB13 is a novel RUNX1 target gene.

Authors:  Anita Boyapati; Bing Ren; Dong-Er Zhang
Journal:  Biochem Biophys Res Commun       Date:  2011-06-23       Impact factor: 3.575

2.  Biochemical markers of bone turnover: part I: biochemistry and variability.

Authors:  Markus J Seibel
Journal:  Clin Biochem Rev       Date:  2005-11

3.  Disruption of the Man-6-P targeting pathway in mice impairs osteoclast secretory lysosome biogenesis.

Authors:  Eline van Meel; Marielle Boonen; Haibo Zhao; Viola Oorschot; F Patrick Ross; Stuart Kornfeld; Judith Klumperman
Journal:  Traffic       Date:  2011-05-05       Impact factor: 6.215

Review 4.  [Cathepsin K antagonists: preclinical and clinical data].

Authors:  Marion Gamsjäger; Heinrich Resch
Journal:  Wien Med Wochenschr       Date:  2015-01-09

Review 5.  Oxygen free radicals and redox biology of organelles.

Authors:  Leni Moldovan; Nicanor I Moldovan
Journal:  Histochem Cell Biol       Date:  2004-09-25       Impact factor: 4.304

6.  Membrane-type MMPs enable extracellular matrix permissiveness and mesenchymal cell proliferation during embryogenesis.

Authors:  Joanne Shi; Mi-Young Son; Susan Yamada; Ludmila Szabova; Stacie Kahan; Kaliopi Chrysovergis; Lauren Wolf; Andrew Surmak; Kenn Holmbeck
Journal:  Dev Biol       Date:  2007-10-23       Impact factor: 3.582

7.  MT1-MMP and type II collagen specify skeletal stem cells and their bone and cartilage progeny.

Authors:  Ludmila Szabova; Susan S Yamada; Helen Wimer; Kaliopi Chrysovergis; Signe Ingvarsen; Niels Behrendt; Lars H Engelholm; Kenn Holmbeck
Journal:  J Bone Miner Res       Date:  2009-11       Impact factor: 6.741

8.  Cathepsin K activity-dependent regulation of osteoclast actin ring formation and bone resorption.

Authors:  Susan R Wilson; Christoph Peters; Paul Saftig; Dieter Brömme
Journal:  J Biol Chem       Date:  2008-11-21       Impact factor: 5.157

9.  Serum cathepsin K levels of patients with longstanding rheumatoid arthritis: correlation with radiological destruction.

Authors:  Martin Skoumal; Günther Haberhauer; Gernot Kolarz; Gerhard Hawa; Wolfgang Woloszczuk; Anton Klingler
Journal:  Arthritis Res Ther       Date:  2004-11-10       Impact factor: 5.156

10.  TRAP5b and RANKL/OPG Predict Bone Pathology in Patients with Gaucher Disease.

Authors:  Margarita Ivanova; Julia Dao; Lauren Noll; Jacqueline Fikry; Ozlem Goker-Alpan
Journal:  J Clin Med       Date:  2021-05-20       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.